RESUMEN
In this experiment, the murine melanoma cell B16-F10 oncolysates transfected by recombinant vaccinia viruses encoding human IL-2(IL-2VBO) were used as vaccine. When the tumor-bearing mice were treated by following injection of IL-2VBO into tumor site, the tumor growth was inhibited and the survival time prolonged. The PBL from IL-2VBO treated mice showed higher cytotoxicity to the wild type B16-F10 but not to YAC-1 cells than that from control groups. The results showed the active specific immunity was induced by the IL-2VBO. On accout of its stronger immuogenicity and some advantages in preparing and storing, the IL-2VBO might be used as a kind of effective vaccine in the cancer active specific immunotherapy.
RESUMEN
The Ad-IL-2 and/or Ad-IL-3 were i. p. injected into experimental leukemic mice after high dose chemotherapy. When Ad - LacZ was i. p. injected into leukemic mice, there were leukemic cells in bone marrow, vessal, liver and spleen. After i. p. injection of Ad-IL-2 and/or Ad-IL-3, the leukemia - bearing mice showed significant inhibition of tumor growth. As i.p. injection of Ad-IL-2, the splenic NK, CTL activity increased; as i. p. injection of Ad - IL - 3, the number and cytotoxicity of peritoneal macrophages were significantly higher than that of the control groups. After i. p. injection of Ad - IL - 2 and Ad - IL - 3 at the same time, the anti - leukemia activity was the best. Though there were less leukemic cells in the bone marrow, there were no leukemic cells in the liver and spleen. Our results suggested that i. p. injection of Ad - IL - 2 and Ad - IL - 3 could significantly enhance the anti - leukemia activity of chemotherapy.
RESUMEN
The titer of Interleukin-2 (IL-2), prepared from the healthy human peripheral blood lymphoytes which were stimulating-induced by carboxymethy-parchymaran (CMP), was very high and reached clinical drug level after special process. The IL-2 was not only available for intramuscular injection. but also for intravenous in jection or even for intraarterial, injection 44 partients with advanced malignant tumor treated with the combination of IL-2 / LAK and chemotherapy showed an overall objective response rate to 86. 4% (CR + PR: 13, 29.3%); (CR + PR + MR: 22, 50%); (CR + PR + MR + SR : 38, 86. 4%) . 37 Patients with various malignant tumors were treated by low-dose interleukin-2 stinulated with CMP and irradiation with 60Co. The percentages of CR, PR and SR were 51.4%, 46.8%and 2.7%, respectively. Overall effectiveness rate was 97.3%. 1 year survival rate was 86.2%. 16 Patients with various advanced cancers were treated by low-dose interleukin-2 stimulated with CMP and low - dose radiotherapy or chemotherapy. The percentage of CR, PR and SR was 37. 5%, 56. 3%and 6 . 3%, respectively. Overall effective rate was 93. 8%. 1 year survival rate was 87. 5%. The current results indicate that the possibility of combined therapy of the low - dose IL-2/LAK adoptive chemoimmunotherapy and radiotherapy or chemotherapy may be effective in treatment of advanced cancer.